Lifecore Biomedical (Lifecore Biomedical) Cash Conversion Cycle : 250.26 (As of May. 2023)

Lifecore Biomedical Cash Conversion Cycle Chart

Lifecore Biomedical Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	May23
Cash Conversion Cycle		Get a 7-Day Free Trial					39.37	188.61	393.87	307.28	220.31

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Cash Conversion Cycle	Get a 7-Day Free Trial															445.34	170.67	230.41	288.68	250.26

Competitive Comparison of Lifecore Biomedical's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cash Conversion Cycle falls into.

Lifecore Biomedical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Lifecore Biomedical's Cash Conversion Cycle for the fiscal year that ended in May. 2023 is calculated as

Lifecore Biomedical's Cash Conversion Cycle for the quarter that ended in May. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical  (NAS:LFCR) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Lifecore Biomedical Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description